Most Recent Episode
Rewriting the Future of Rare Cardiovascular Disease Through Epigenetic Innovation In this episode of BioBiz Buzz, your host Mike Ward sits down with Sten R. Sörensen, CEO of Cereno Scientific, to explore how the Swedish biotech is pioneering a new era in rare cardiovascular and pulmonary disease therapeutics.
Cereno’s lead candi
Time: 23:29
In this episode of BioBiz Buzz, your host Mike Ward sits down with Sten R. Sörensen, CEO of Cereno Scientific, to explore how the Swedish biotech is pioneering a new era in rare cardiovascular and pulmonary disease therapeutics.
Cereno’s lead candidates, CS1 and CS014, leverage epigenetic modulation through histone deacetylase inhibition (HDACi) to address the root causes of diseases like pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF), aiming to reverse pathological remodeling and prevent thrombosis-without the bleeding risks of traditional therapies.
Sörensen discusses the company’s strategic pivot to rare diseases, the science behind their innovative pipeline, and the impact of recent SEK250 million financing on accelerating clinical programs. The conversation also highlights Cereno’s approach to partnerships, regulatory milestones, and the transformative potential of targeting gene expression in cardiovascular drug development.
Tune in for a deep dive into the future of disease-modifying therapies and the milestones shaping Cereno’s journey in 2025
● Feedback
● Subscribe (Get notified when new episodes are available. NO marketing!)
● Disclaimer
● LinkedIn
● Bluesky
GUID: Buzzsprout-17046684
Release Date: 02/05/2025, 15:00:00
